J&J, Bavarian Nordic and GSK involved in upcoming Ebola vax trials; Researchers develop rheumatoid arthritis immunotherapy;

> Upcoming Ebola vaccine trials in Ghana will be led by Johnson & Johnson ($JNJ) and Bavarian Nordic in Phase I and GlaxoSmithKline ($GSK) in Phase II. Report

> Australia's University of Queensland researchers developed an immunotherapy for people with the most common form of rheumatoid arthritis. More

> Cellular Biomedicine Group ($CBMG) acquired from Blackbird Bio Finance a cancer vaccine to be used in a trial of non-small cell lung cancer. Release

> A cancer vaccine from Australia's Regenus, originally tried in dogs, will be used in 21 humans with advanced cancers who have exhausted all available treatment regimens. Report

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.